आयात शुल्क वाढविल्याने शेतमालाच्या किमती सावरल्या

केंद्राकडून शेतकऱ्यांना दिलासा; आंदोलनाने सरकारला जाग

अशोक तुपे, श्रीरामपूर

शेतमालाच्या कोसळणाऱ्या किमती सावरण्यासाठी आयात शुल्क वाढवून निर्यात शल्क कमी करण्याची मात्रा उपयोगी ठरली. केंद्र सरकारने शेतकऱ्याच्या वेदना कमी करण्यासाठी उशिरा का होईना निर्णय घेतले आहेत. गेल्या त्यामुळे आता शेतीक्षेत्रातील अस्वस्थता काही प्रमाणात कमी करण्यात यश आले

साखर, कांदा, तांदूळ, सोयाबीन, हरभरा, वटाणा, तूर, गहू याच्या किमती आंतरराष्ट्रीय बाजारातील चढउतारावर मोठ्या प्रमाणात अवलंबन असतात. गेल्या तीन वर्षापासून किंमती कोसळत होत्या. गेल्या वर्षी तर दर नीचांकी होते. त्यामुळे शेतकऱ्यांमध्ये अस्वस्थता होती. त्यातून मध्यप्रदेश, महाराष्ट्र, गुजरात, उत्तर प्रदेशमध्ये आंदोलने झाली. विशेष म्हणजे गुजरातच्या निवडणुकीपुर्वी त्याची धग जाणव् लागल्याने सरकारने किंमती सावरण्याचा प्रयत्न केला. त्याकरिता प्रथमच ७ ते ८ वर्षांनंतर अनेक मालांच्या आयात शुल्कात वाढ केली.



त्यामुळे काही शेतमालाच्या किमतीत स्थिरता आली. शहरी मध्यमवर्गीयांचे सरकार अशी टीका खोड्न काढण्यासाठी अर्थसंकल्पापूर्वीच हे निर्णय घेण्यात आले होते.

पामतेलावर ५० टक्के तर सोयाबीन तेलावर ४० टक्के शुल्क आकारले. त्यामुळे दर सावरले. विशेष म्हणजे हा निर्णय घेण्यास सरकारला उशिरा झाला. यातन शेतकरी सावरला, असे मत सोयाबीन एक्स्ट्रॅक्ट प्रोसेसिंग असोसिएशनचे कार्यकारी संचालक डी.एन.पाठक यांनी केले. आंतरराष्ट्रीय बाजारपेठेवर सोयाबीनचे दर अवलंबून असतात. आता अर्जेंटिना व ब्राझीलमध्ये उत्पादन घटल्याने तेथे चार हजार रुपये क्विंटलने सोयाबीन विकले जात आहे. सोयापेंडचे (डीओसी) दर सोयाबीनचे वाढले. याचा फायदा शेतकऱ्यांना

झाला. पण हा निर्णय लवकर घेणे गरजेचे होते. असे धुळे येथील ऑईल मिल मालक मनोज अग्रवाल यांचे म्हणणे आहे. मसूर आणि हरभरा उत्पादन यंदा जास्त होणार आहे. बाजारातील हरभरा दर कोसळले होते. त्यामुळे आयात शुल्कात वाढ करण्याची मागणी केली जात होती. सरकारने मसूर व हरबऱ्यावर आता ४० टके आयात शुल्क लागू केले आहे. त्याचा फायदा कोसळणारे दर सावरण्यास सुरुवात झाली आहे. डाळीवरील आयात शुल्कात सरकारने प्रथमच मोठी वाढ केली.

कांदा उत्पादकांना दिलासा कांद्याच्या किंमती पाडण्यासाठी सरकार किमान निर्यातमुल्यात वाढ करत असते. यंदा सरकारने निर्यातमुल्य (एमईपी) वाढविल्याने कांद्याच्या किंमती कोसळल्या होत्या.त्यामुळे कांदा उत्पादक शेतकरी संतप्त झाले होते. मात्र या महिन्यात पहिल्याच आठवड्यात किमान निर्यातमुल्य हटविण्याचा निर्णय घेण्यात त्यामुळे कांदा उत्पादकांना दिलासा मिळाला आहे.

एसटी कर्मचाऱ्यांच्या वेतनवाढीवरील चर्चा फिस्कटली

मान्यताप्राप्त संघटना आपल्या मागणीवर ठाम

प्रतिनिधी, मुंबई

वेतनवाढीसंदर्भात महामंडळाच्या मुंबईतील मुख्यालयात कामगार संघटना आणि अधिकाऱ्यांत झालेली चर्चा फिस्कटली. वेतनवाढीवर संघटना आपल्या मागण्यावर ठाम राहिली आणि एसटी महामंडळाने ठेवलेला प्रस्ताव नाकारला. त्यामुळे चर्चेची पहिली फेरी विस्कटल्यानंतर येत्या दहा दिवसांत वेतनवाढीवर चर्चेची दुसरी फेरी होणार आहे.

सातवा वेतन आयोगाप्रमाणेच वेतनवाढ देण्यात यावी, अशी मागणी महाराष्ट्र एसटी कामगार संघटनेसह अन्य पाच संघटनांनी केली आहे. त्यासाठी पुढील चार वर्षाचा वेतन करारही करण्यात आलेला नाही. महामंडळाकडून वेतनवाढीसंदर्भात उच्चस्तरीय समितीही नेमण्यात आली आहे. मात्र या समितीचा अहवाल एसटी संघटनांकडून अमान्य करण्यात आला आहे. वेतनवाढीवर तोडगा निघावा यासाठी गुरुवारी एसटीच्या मुंबई सेन्ट्रल येथील मुख्यालयात एसटी संघटना आणि अधिकाऱ्यांत बैठक घेण्यात आली. यावेळी एसटी प्रशासनाने उच्चस्तरीय



समितीने दिलेला ७४१ कोटी रुपयांचा भाराचा प्रस्ताव स्विकारण्याची विनंती संघटनेला करण्यात आली. परंतु संघटनेकडून त्याला स्पष्ट नकार देण्यात आला.

संघटनेने दिलेला प्रस्ताव ३१ मार्च २०१६ चे मूळ वेतन आणि ३,५०० गुणिले २.५७ यावर चर्चा करण्याची मागणी करण्यात आली. एसटी संपाच्या दुसऱ्या दिवशी एसटी अध्यक्षांनी दिलेला सुमारे १,०७६ कोटींचा प्रस्तावात समाधानकारक वाढ होत नसल्याने संघटनेने प्रशासनाचा सद्याचा प्रस्ताव मान्य करणे कदापि शक्य नसल्याचे महाराष्ट्र एसटी कामगार संघटनेचे अध्यक्ष संदिप शिंदे यांनी सांगितले. यासंदर्भात एसटी आणि संघटनेत आठवडाभरात दुसरी चर्चेची फेरी होणार असल्याची माहिती त्यांनी

विदर्भात रविवारी गारांचा पाऊस पडण्याचा हवामान खात्याचा अंदाज

मध्य महाराष्ट्र, मराठवाड्यातील काही भागांमध्ये पावसाची शक्यता

प्रतिनिधी, मुंबई

मालदीवपासून भारताच्या पश्चिम किनारपट्टीपर्यंत निर्माण झालेल्या कमी दाबाच्या पट्ट्यामुळे येत्या रविवारी म्हणजेच ११ फेब्रुवारीला विदर्भात गडगडाटासह गारांचा पाऊस अंदाज हवामान खात्याकड्न वर्तविण्यात आला आहे. तसेच रविवारपासून विदर्भासह मध्य महाराष्ट्र, मराठवाडातील काही भागांमध्ये गडगडाटासह पावसाची शक्यता असल्याचेही हवामान

खात्याकडन सांगण्यात आले आहे. दिवसांच्या वातावरणानंतर कोकण, गोवा, मध्य महाराष्ट्र आणि मराठवाडा या भागातील किमान तापमानामध्ये एक ते तीन अंश.संं. घसरण झाली आहे. कोकण आणि गोव्यामध्ये काही तुरळक ठिकाणी गुरुवारी पावसाच्या सरी पडल्या आहेत. तसेच मुंबईमध्ये ही किमान तापमानामध्ये एक ते दोन अंश.सें. घसरण झाल्याचे नोंदविण्यात आले आहे.

कमी दाबाचा पट्टा पश्चिमेकडे

सरकत असल्याने येत्या शनिवारी विदर्भात तुरळक मेघगर्जनेसह पाऊस पडण्याची शक्यता आहे. रविवारीदेखील ही स्थिती कायम राहणार असुन विदर्भामध्ये गारांचा पाऊस पडण्याची शक्यता असल्याचे वेधशाळेकडून सांगण्यात आले आहे. शनिवारपासून पुढील दोन दिवस विदर्भासह मराठवाडा, मध्य महाराष्ट्रामध्येही गडगडाटासह पावसाच्या सरी अंदाज हवामान खात्याकडून सांगण्यात आला आहे

बी.टी. बियाणांच्या चौकशीसाठी पुन्हा 'एसआयटी'

यवतमाळः बीटी कापूस बियाणामध्ये परवानगी नसलेले तणनाशकाला प्रतिबंध करणारे जीन्स आढळून आल्याने चौकशी करण्यासाठी राज्याचे गुप्तवार्ता विभागाचे आयुक्त संजय बर्वे यांच्या अध्यक्षतेखाली शासनाने पुन्हा विशेष तपास पथक अर्थात एसआयटी स्थापना केली

आहे. कृषी व पशुसंवर्धन खात्याने ७ फेब्रुवारीला यासंदर्भात आदेश जारी केले आहेत.

समितीचे सचिव सदस्य म्हणूनअमरावती विभागाचे कृषी सहसंचालक सुभाष नागरे यांची नियुक्ती करण्यात आली आहे. समिती एक महिन्याच्या आत अहवाल सादर

अवैधरित्या बी.टी. बियाणांची विक्री करणाऱ्या कंपन्यांची चौकशी आदेश सरकारने राज्य सरकारला दिले एसआयटी चौकशी करून उपायही सुचवणार



Registered Office: B/2, Mahalaxmi Chambers, 22, Bhulabhai Desai Road, Mumbai 400 026.

Corporate Office: Glenmark House, B. D. Sawant Marg, Chakala, Andheri (East), Mumbai 400 099.

Tel: 91 22 4018 9999 Fax: 91 22 4018 9986 Email: complianceofficer@glenmarkpharma.com Website: www.glenmarkpharma.com

CIN: L24299MH1977PLC019982

Statement of Profit and Loss for the quarter and nine months ended 31 December, 2017

Particulars (Refer note below)				Standalor	ne (Ind AS)		-		Cc	onsolidated (In	Ind AS)			Consolidated (IFRS)						
Revenue from operations (a) Net sales (a) Net sales (b) Cher sales (b) Cher sales (c) Cher sales	(0.5) 424 (0.5) 56 (6.5) 1.5 (0.5)	ended 31-12-2017	ended 30-09-2017	Quarter ended 31-12-2016	Nine Months ended 31-12-2017	ended 31-12-2016	ended 31-03-2017	ended 31-12-2017	Quarter ended 30-09-2017	Quarter ended 31-12-2016	Nine Months ended 31-12-2017	ended 31-12-2016	ended 31-03-2017	ended 31-12-2017	ended 30-09-2017	Quarter ended 31-12-2016	Nine Months ended 31-12-2017	ended 31-12-2016	ended 31-03-2017	
No persisting incomes 14,982,48 14,982,58 27,843,89 27,853,89 27,843,89 27,755,90 27,755,90 27,843,99 28,843,19 27,845,99 27,8	Paragraphic from apprehings	(Onaudited)	(Onaddited)	(Onaudited)	(Onaudited)	(Onaddited)	(Audited)	(Onaudited)	(Onaudited)	(Unaudited)	(Onaudited)	(Onaudites)	(Addition)	(Onaudited)	(Onaddited)	(Onauditou)	(Onaddited)	(Onaudited)	(Addited)	
Description Properties Pr	The state of the s	11 500 46	40 10E E	04 440 44	45 207 05	57 500 00	70 040 00	04 745 05	00 004 40	04 000 51	07 040 00	05 450 70	20 700 00	04 745 05	00 004 4/	04 000 50	07.040.00	05 450 70	20 700 00	
New n																				
Note Profit												-								
No. Expanse		25		188			3			20		1/2	89	Samuel		8		5		
V Expenses Cost of materials consumed 5,24,70 4,848,22 5,615,27 15,073,13 16,941,38 2,420,13 5,051,16 5,443,85 5,600,86 15,351,86 18,358,44 23,548,13 5,051,16 5,443,85 5,600,86 15,351,86 18,358,44 23,548,13 5,051,16 5,443,85 5,600,86 15,351,86 18,358,44 23,548,13 5,051,16 5,443,85 5,600,86 15,351,86 18,358,44 23,548,13 5,051,16 5,443,85 5,600,86 15,351,86 18,358,44 23,548,13 5,051,16 5,443,85 5,600,86 15,351,86 18,358,44 23,548,13 5,051,16 5,443,85 5,600,86 15,351,86 18,358,44 23,548,13 5,051,16 5,443,85 5,600,86 15,351,86 18,358,44 23,548,13 5,051,16 5,443,85 5,600,86 15,351,86 18,358,44 23,548,13 5,051,16 5,443,85 5,600,86 15,351,86 18,358,44 23,548,13 5,051,16 5,443,85 5,600,86 15,351,86 18,358,44 23,548,13 5,051,16 5,443,85 5,600,86 15,351,86 18,358,44 23,548,13 5,051,16 5,443,85 5,600,86 15,351,86 18,358,44 23,548,13 5,051,16 5,443,85 5,600,86 15,351,86 18,358,44 23,548,13 5,051,16 5,443,85 5,600,86 15,351,86 18,358,44 23,548,13 5,051,16 5,443,85 5,600,86 15,351,86 18,358,44 23,548,13 5,051,16 5,443,85 5,600,86 15,351,86 18,358,44 23,548,13 5,051,16 5,443,85 5,600,86 15,351,86 18,358,44 23,548,13 5,051,16 5,443,85 5,600,86 15,351,86 18,358,44 23,548,13 5,051,16 5,443,85 5,600,86 13,351,86 18,358,44 23,548,13 13,451,14 1		100000000000000000000000000000000000000												- 10 TO TO THE						
Cost of materials consumed 5,224,70 4,946,22 5,615,27 15,073,13 16,941,38 2,420,13 5,051,16 5,443,85 5,000,88 15,351,68 13,351		15,937.81	17,161.16	22,981.37	49,002.63	62,289.01	82,437.39	21,804.98	22,863.16	25,495.75	68,451.02	68,171.50	92,230.46	21,804.98	22,863.16	25,495.01	68,451.02	68,170.75	92,229.71	
Purchase of stock-in-trade	260	1	1	1		1		1 1	1		1 /				1		1	1	1	
Changes in inventroites of finished goods, work-in-progress and stock-in-trade 2,553.98 3,264.26 2,274.07 7,895.91 6,933.45 9,144.71 4,659.42 5,572.30 4,016.81 14,075.68 12,560.66 16,408.06 4,659.42 5,572.30 4,016.81 14,075.68 12,560.66 16,408.06 4,659.42 5,572.30 4,016.81 14,075.68 12,560.66 16,408.06 4,659.42 5,572.30 4,016.81 14,075.68 12,560.66 16,408.06 4,659.42 5,572.30 4,016.81 14,075.68 12,560.66 16,408.06 4,659.42 5,572.30 4,016.81 14,075.68 12,560.66 16,408.06 4,659.42 5,572.30 4,016.81 14,075.68 12,560.66 16,408.06 4,659.42 5,572.30 4,016.81 14,075.68 12,560.66 16,408.06 4,659.42 5,572.30 4,016.81 14,075.68 12,560.66 16,408.06 4,659.42 5,572.30 4,016.81 14,075.68 12,560.66 16,408.06 4,659.42 5,572.30 4,016.81 14,075.68 12,560.66 16,408.06 4,659.42 5,572.30 4,016.81 14,075.68 12,560.66 16,408.06 4,659.42 5,572.30 4,016.81 14,075.68 12,560.66 16,408.06 4,659.42 5,572.30 4,016.81 14,075.68 12,560.66 16,408.06 4,659.42 5,572.30 4,016.81 14,075.68 12,560.66 16,408.0		77.000000	A STATE OF THE STA																	
Work-in-progress and stock-in-trade Sa4.49 Sa4.97 72.99 71.11 Sa5.19 Sa5.19 Sa5.17 Sa5.19 S	Purchase of stock-in-trade	891.95	664.07	661.52	2,249.08	2,109.63	2,669.96	1,862.11	1,342.18	1,578.60	5,813.45	3,584.74	7,191.20	1,862.11	1,342.18	1,578.60	5,813.45	3,584.74	7,191.20	
Employee benefits expense			1	/											/					
Finance costs Depreciation and Amortisation expense Difference costs Depreciation and Amortisation expense Difference costs Other expenses Ot																		1000		
Depreciation and Amortisation expense		100000000000000000000000000000000000000				100 SESSION				1 1980 550				18.500.000						
Other expenses Total expenses (IV) 13,663.09 13,386.00 14,232.48 19,765.07 39,843.66 54,543.92 20,268.27 20,132.66 18,942.47 59,742.39 54,997.53 76,506.67 20,409.66 20,254.81 19,105.39 60,106.52 55,355.22 77,030.6 1 2,703.6 1	Finance costs	469.99	474.41	495.39	1,401.76	1,028.81	1,526.02	704.74	698.44	617.37	2,111.79	1,676.48	2,373.18	704.74	698.44	617.37	2,111.79	1,676.48	2,373.18	
Total expenses (IV) 13,663.05 13,386.90 14,232.48 39,755.07 39,843.66 54,543.92 20,132.66 18,942.47 59,742.39 54,987.33 76,566.67 20,409.66 20,254.81 19,105.39 60,106.52 55,355.22 77,030.66 12,107.10 10,107	Depreciation and Amortisation expense	295.53	288.93	263.36	883.86	776.15	1,049.32	753.84	752.28	625.26	2,283.44	1,954.64	2,643.68	895.18	874.05	788.44	2,646.43	2,322.33	3,167.61	
V Profit/(loss) before exceptional items and tax (III - IV) Exceptional items (refer note 5) V Exceptional items (refer n	Other expenses	4,531.39	3,262.04	4,849.88	12,080.19	12,890.43	18,568.95	6,334.56	5,597.17	7,692.64	18,728.84	20,421.97	28,938.49	6,334.61	5,597.55	7,692.38	18,729.98	20,421.97	28,938.49	
tax (III - IV) tax (I	Total expenses (IV)	13,663.05	13,386.90	14,232.48	39,755.07	39,843.66	54,543.92	20,268.27	20,132.66	18,942.47	59,742.39	54,987.53	76,506.67	20,409.66	20,254.81	19,105.39	60,106.52	55,355.22	77,030.60	
VII Profit/(loss) before tax (V - VI)	10 100000000000000000000000000000000000	200000000000000000000000000000000000000						200000000000000000000000000000000000000	0924/20040	2000		Barrell Street					2000-2000-000		000000000000000000000000000000000000000	
VII Profit/(loss) before tax (V - VI)	tax (III - IV)	2,274.76	3,774.26	8,748.89	9,247.56	22,445.35	27,893.47	1,536.71	2,730.50	6,553.28	8,708.63	13,183.97	15,723.79	1,395.32	2,608.35	6,389.62	8,344.50	12,815.53	1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1	
VIII Tax expense : Current tax 489.59 801.35 1,946.54 1,973.25 4,888.25 6,040.24 (302.31) (19.77.36) (308.89) 283.76 (109.27) (626.03) (2,363.66) (68.41) (410.95) 293.14 (183.43) (692.36) (2,735.6 8,772.9 8,713.07 7,928.35 1,946.54 1,947.10 1,941.16 3,278.79 7,113.07 7,928.35 1,946.54 1,947.25 4,888.25 6,040.24 529.15 976.19 1,498.51 2,295.47 4,535.33 6,190.43 529.15 976.19 1,498.51 2,295.47 1,098.51 2,295.47 1,098.53 32.03 (77.00) (47.01) (2.84) 50.33 (35.32) 32.03 (77.00) (47.01) (2.84) 50.33 (35.32) 32.03 (77.00) (47.01) (2.84) 50.33 (35.32) 32.03 (77.00) (47.01) (2.84) 50.33 (35.32) 32.03 (77.00) (47.01) (2.84) 50.33 (35.32) 32.03 (77.00) (47.01) (2.84) 50.33 (35.3	VI Exceptional items (refer note 5)		1	1	10	1	2,364.51		-	7	1	-	809.49	-		7	4	7	2,597.59	
Current tax	VII Profit/(loss) before tax (V - VI)	2,274.76	3,774.26	8,748.89	9,247.56	22,445.35	25,528.96	1,536.71	2,730.50	6,553.28	8,708.63	13,183.97	14,914.30	1,395.32	2,608.35	6,389.62	8,344.50	12,815.53	12,601.52	
Deferred tax (155.99) (305.88) (310.72) (654.04) (302.31) (1,917.36) (39.87) (386.89) 283.76 (109.27) (626.03) (2,363.66) (68.41) (410.95) 293.14 (183.43) (692.36) (2,735.64) (VIII Tax expense :	1	/	1	/	1		1	1		/						/			
X Profit/(loss) for the period (VII - VIII 1,941.16 3,278.79 7,113.07 7,928.35 17,859.40 21,406.08 1,047.43 2,141.20 4,771.01 6,522.43 9,274.67 11,087.53 934.58 2,043.11 4,597.97 6,232.46 8,972.56 9,159.20 1,047.01 1,047	Current tax	489.59	801.35	1,946.54	1,973.25	4,888.25	6,040.24	529.15	976.19	1,498.51	2,295.47	4,535.33	6,190.43	529.15	976.19	1,498.51	2,295.47	4,535.33	6,177.97	
X Other comprehensive income A (i) Items that will not be reclassified to profit or loss (ii) Income tax relating to items that will not be reclassified to profit or loss 4.12 9.02 5.87 16.13 23.90 11.70 2.94 (1.02) 12.00 5.90 24.75 13.29 2.94 (1.02) 12.00 5.90 24.75 13.29 B (i) Items that will be reclassified to profit or loss (ii) Income tax relating to items that will be reclassified to profit or loss (ii) Income tax relating to items that will be reclassified to profit or loss (iii) Income tax relating to items that will be reclassified to profit or loss (iii) Income tax relating to items that will be reclassified to profit or loss (iii) Income tax relating to items that will be reclassified to profit or loss (iv) Income tax relating to items that will be reclassified to profit or loss (iv) Income tax relating to items that will be reclassified to profit or loss (iv) Income tax relating to items that will be reclassified to profit or loss (iv) Income tax relating to items that will be reclassified to profit or loss (iv) Income tax relating to items that will be reclassified to profit or loss (iv) Income tax relating to items that will be reclassified to profit or loss (iv) Income tax relating to items that will be reclassified to profit or loss (iv) Income tax relating to items that will be reclassified to profit or loss (iv) Income tax relating to items that will be reclassified to profit or loss (iv) Income tax relating to items that will be reclassified to profit or loss (iv) Income tax relating to items that will be reclassified to profit or loss (iv) Income tax relating to items that will be reclassified to profit or loss (iii) Income tax relating to items that will be reclassified to profit or loss (iv) Income tax relating to items that will be reclassified to profit or loss (iii) Income tax relating to items that will be reclassified to profit or loss (iii) Income tax relating to items that will be reclassified to profit or loss (iii) Income tax relating to items that will be reclassified to profit o	Deferred tax	(155.99)	(305.88)	(310.72)	(654.04)	(302.31)	(1,917.36)	(39.87)	(386.89)	283.76	(109.27)	(626.03)	(2,363.66)	(68.41)	(410.95)	293.14	(183.43)	(692.36)	(2,735.66)	
A (i) Items that will not be reclassified to profit or loss (ii) Income tax relating to items that will not be reclassified to profit or loss (ii) Income tax relating to items that will be reclassified to profit or loss (ii) Income tax relating to items that will be reclassified to profit or loss (ii) Income tax relating to items that will be reclassified to profit or loss (iii) Income tax relating to items that will be reclassified to profit or loss (iii) Income tax relating to items that will be reclassified to profit or loss (iii) Income tax relating to items that will be reclassified to profit or loss (iii) Income tax relating to items that will be reclassified to profit or loss (iii) Income tax relating to items that will be reclassified to profit or loss (iii) Income tax relating to items that will be reclassified to profit or loss (iii) Income tax relating to items that will be reclassified to profit or loss (iii) Income tax relating to items that will be reclassified to profit or loss (iii) Income tax relating to items that will be reclassified to profit or loss (iii) Income tax relating to items that will be reclassified to profit or loss (iii) Income tax relating to items that will be reclassified to profit or loss (iii) Income tax relating to items that will be reclassified to profit or loss (iii) Income tax relating to items that will be reclassified to profit or loss (iii) Income tax relating to items that will be reclassified to profit or loss (iii) Income tax relating to items that will be reclassified to profit or loss (iii) Income tax relating to items that will be reclassified to profit or loss (iii) Income tax relating to items that will be reclassified to profit or loss (iii) Income tax relating to items that will be reclassified to profit or loss (iii) Income tax relating to items that will be reclassified to profit or loss (iii) Income tax relating to items that will be reclassified to profit or loss (iii) Income tax relating to items that will be reclassified to profit or loss (iii) Incom	IX Profit/(loss) for the period (VII - VIII)	1,941.16	3,278.79	7,113.07	7,928.35	17,859.40	21,406.08	1,047.43	2,141.20	4,771.01	6,522.43	9,274.67	11,087.53	934.58	2,043.11	4,597.97	6,232.46	8,972.56	9,159.21	
(ii) Income tax relating to items that will not be reclassified to profit or loss B (i) Items that will be reclassified to profit or loss (ii) Income tax relating to items that will be reclassified to profit or loss (iii) Income tax relating to items that will be reclassified to profit or loss (ii) Income tax relating to items that will be reclassified to profit or loss XI Total comprehensive income 1,933.36 3,261.72 7,077.77 7,897.87 17,789.10 21,383.38 1,148.95 2,176.10 4,354.94 6,292.86 9,695.78 9,303.81 996.89 2,148.15 4,240.70 6,038.14 9,441.14 7,366.79 1.00 1.00 1.00 1.00 1.00 1.00 1.00 1.0	X Other comprehensive income	1	/	1				1	1						/		1			
(ii) Income tax relating to items that will not be reclassified to profit or loss B (i) Items that will be reclassified to profit or loss (ii) Income tax relating to items that will be reclassified to profit or loss (iii) Income tax relating to items that will be reclassified to profit or loss XI Total comprehensive income 1,933.36 3,261.72 7,077.77 7,897.87 16.13 23.90 11.70 2.94 (1.02) 12.00 5.90 24.75 13.29 2.94 (1.02) 12.00 2.94 (1.02) 12.00 2.94 (1.02) 12.00 2.94 (1.02) 12.00 2.94 (1.02) 12.00 2.94 (1.02) 12.00 2.94 (1.02) 12.00 2.94 (1.02) 12.00 2.94 (1.02) 12.00 2.94 (1.02) 12.00 2.94 (1.02) 12.00 2.94 (1.02) 12.00 2.94 (1.02) 12.00 2.94 (1.02) 12.00 2.94 (1	A (i) Items that will not be reclassified to profit or loss	(11.92)	(26.09)	(41.17)	(46.61)	(94.20)	(34.40)	(2.84)	50.33	(35.32)	32.03	(77.00)	(47.01)	(2.84)	50.33	(35.32)	32.03	(77.00)	(47.01)	
B (i) Items that will be reclassified to profit or loss (ii) Income tax relating to items that will be reclassified to profit or loss XI Total comprehensive income Total comprehensive income attributable to: 101.42 (14.41) (392.75) (267.50) 473.36 (1,750.00) 62.21 55.73 (333.95) (232.25) 520.83 (1,758.77) 101.42 (14.41) (392.75) (267.50) 473.36 (1,750.00) 62.21 55.73 (333.95) (232.25) 520.83 (1,758.77) 101.42 (14.41) (392.75) (267.50) 473.36 (1,750.00) 62.21 55.73 (333.95) (232.25) 520.83 (1,758.77) 101.42 (14.41) (392.75) (267.50) 473.36 (1,750.00) 62.21 55.73 (333.95) (232.25) 520.83 (1,758.77) 101.42 (14.41) (392.75) (267.50) 473.36 (1,750.00) 62.21 55.73 (333.95) (232.25) 520.83 (1,758.77) 101.42 (14.41) (392.75) (267.50) 473.36 (1,750.00) 62.21 55.73 (333.95) (232.25) 520.83 (1,758.77) 101.42 (14.41) (392.75) (267.50) 473.36 (1,750.00) 62.21 55.73 (333.95) (232.25) 520.83 (1,758.77) 101.42 (14.41) (392.75) (267.50) 473.36 (1,750.00) 62.21 55.73 (333.95) (232.25) 520.83 (1,758.77) 101.42 (14.41) (392.75) (267.50) 473.36 (1,750.00) 62.21 55.73 (333.95) (232.25) 520.83 (1,758.77) 101.42 (14.41) (392.75) (267.50) 473.36 (1,750.00) 62.21 55.73 (333.95) (232.25) 520.83 (1,758.77) 101.42 (14.41) (392.75) (267.50) 473.36 (1,750.00) 62.21 55.73 (267.50) 473.36 (1,750.00) 62.21 55.73 (27.50) 473.36 (1,750.00) 62.21 55.73 (27.50) 473.36 (1,750.00) 62.21 55.73 (27.50) 473.36 (1,750.00) 62.21 55.73 (27.50) 473.36 (1,750.00) 62.21 55.73 (27.50) 473.36 (1,750.00) 62.21 55.73 (27.50) 473.36 (1,750.00) 62.21 55.73		4.12	9.02	5.87	16.13	23.90	11.70	2.94	(1.02)	12.00	5.90	24.75	13.29	2.94	(1.02)	12.00	5.90	24.75	13.29	
(ii) Income tax relating to items that will be reclassified to profit or loss XI Total comprehensive income attributable to: 1,933.36 3,261.72 7,077.77 7,897.87 17,789.10 21,383.38 1,148.95 2,176.10 4,354.94 6,292.86 9,695.78 9,303.81 996.89 2,148.15 4,240.70 6,038.14 9,441.14 7,366.7	B (i) Items that will be reclassified to profit or loss			4	139		4	101.42	(14.41)	(392.75)	(267.50)	473.36	(1,750.00)	62.21		100 m 2 4 5 1 4 5 1 6 5	(232.25)	520.83	(1,758.73)	
XI Total comprehensive income 1,933.36 3,261.72 7,077.77 7,897.87 17,789.10 21,383.38 1,148.95 2,176.10 4,354.94 6,292.86 9,695.78 9,303.81 996.89 2,148.15 4,240.70 6,038.14 9,441.14 7,366.7 XII Total comprehensive income attributable to:	(ii) Income tax relating to items that will be																			
XII Total comprehensive income attributable to:	AND	1,933.36	3,261.72	7,077.77	7,897.87	17,789.10	21,383.38	1,148.95	2,176.10	4,354.94	6,292.86	9,695.78	9,303.81	996.89	2,148.15	4,240.70	6,038.14	9,441.14	7,366.76	
				12.000 (0.000)	Balling Secret			300000000000000000000000000000000000000	000000000000000000000000000000000000000	S. Cherrie Control		0.5,121213-12	E. A		2000000000	97.263.263	E-8/18/18/18/18		735	
			4	4	4 4	4 4		0.64	(0.32)	0.71	0.45	0.71	(0.46)	0.64	(0.32)	0.71	0.45	0.71	(0.46)	
- Owners of the Company 1,933.36 3,261.72 7,077.77 7,897.87 17,789.10 21,383.38 1,148.31 2,176.42 4,354.23 6,292.41 9,695.07 9,304.27 996.25 2,148.47 4,239.99 6,037.69 9,440.43 7,367.2		1.933.3€	3.261.72	7.077.77	7.897.87	17.789.10	21.383.38			32270							3			
XIII Earning Per Share (of Re 1/- each) (not annualised)		1,10551.5			1,00		2.1,000				Jacob	0,000				1,000	3,021.102		1,100	
		6.88	11.62	25.21	28.10	63.29	75.86	3.71	7.59	16.91	23.12	32 87	39.29	3.31	7.24	16.29	22.05	31.80	32.46	
				100000	1100000					1		100.000		1000				1500000		
Notes:		M.M.				55.65				1000		02.00		9.00		10,000				

- The above results were reviewed by the Audit Committee of the Board at its meeting held on 7 February, 2018 and approved at the meeting of the Board of Directors held on 8 February, 2018.
- The results for the quarter and nine months ended 31 December, 2017 presented were subjected to a "Limited Review" by the Statutory auditors of the Company. An unqualified report was issued by them therein. The Company operates in one reportable business segment i.e., Pharmaceuticals.

5 Exceptional items: Stand-alone: Exceptional items for year ended 31 March, 2017 represents impairment loss relating to investment and trade receivables from the Company's subsidiary in Venezuela. The Company has not received approvals from the Venezuelan government to repatriate any amounts during the

year ended 31 March, 2017 and considering the uncertainty around repatriation, the Company believes it's appropriate to impair such investments and trade receivables from the said subsidiary. Consolidated: Exceptional items for year ended 31 March, 2017 represents impairment loss relating to certain intangibles assets under development owing to the Company's future research and development strategy for such products.

4 As at 31 December, 2017, pursuant to Employee Stock Option Scheme 2003, no options were outstanding, which upon exercise are convertible into equivalent number of equity shares.

- The Company has voluntarily presented the consolidated results in accordance with the recognition and measurement principles as per the IFRS in the format as per the regulation 33(1)(c) of the SEBI (Listing and Disclosure Requirements) Regulations, 2015. Post implementation of Goods and Service Tax (GST) with effect from 1 July, 2017, revenue from operations for the earlier period includes excise duty which is now subsumed in the GST. Revenue from operations for the earlier period includes excise duty which is now subsumed in the GST. Revenue from operations for the earlier period includes excise duty which is now subsumed in the GST. Revenue from operations for the earlier period includes excise duty which is now subsumed in the GST.
- 31 December, 2017 includes excise duty upto 30 June, 2017. Accordingly, revenue from operations for the quarter and nine months ended 31 December, 2017 are not comparable with those of previous periods presented.
- The list of subsidiaries as of 31 December, 2017 is provided in Annexure A.

List of entities included in the consolidated financial results for the quarter and Nine Months ended 31 December 2017.

1.Glenmark Pharmaceuticals (Europe) R&D Ltd., U.K. 2.Glenmark Pharmaceuticals S.R.O. 4.Glenmark Pharmaceuticals S.R.O. 5.Glenmark Pharmaceuticals S.R.O. 6.Glenmark Pharmaceutic Pharmaceuticals S.R.L 8.Glenmark Pharmaceuticals SP z.o.o. 9.Glenmark Pharmaceuticals Inc. (formerly known as Glenmark Therapeutics Inc.) 10.Glenmark Farmaceutical Inc. (formerly known as Glenmark Therapeutics Inc.) 11.Glenmark Farmaceutical Inc. (formerly known as Glenmark Therapeutics Inc.) 12.Glenmark Farmaceutical Inc. (formerly known as Glenmark Therapeutics Inc.) 13.Glenmark Therapeutics Inc.) 14.Glenmark Therapeutics Inc.) 15.Glenmark Therapeutics Inc.) 15.Glenmark Therapeutics Inc.) 15.Glenmark Therapeutics Inc.) 16.Glenmark Therapeutics Inc.) 16.Glenmark Therapeutics Inc.) 17.Glenmark Therapeutics Inc.) 17.Glenmark Therapeutics Inc.) 17.Glenmark Therapeutics Inc.) 18.Glenmark Therapeutics Inc.) Pharmaceuticals Mexico, S.A. DE C.V. 14. Glenmark Pharmaceuticals Colombia SAS, Colombia Colombia Colombia Ltda., Colombia Ltda., Colombia Ltda., Colombia Ltda., Colombia Colombia Colombia SAS, Colombia Colombia Colombia Ltda., Colombia Ltda., Colombia Co Pharmaceuticals Venezuela, C.A 18. Glenmark Dominicana SRL 19. Glenmark Pharmaceuticals Egypt S.A.E. 20. Glenmark Pharmaceuticals FZE 21. Glenmark Philippines Inc. 23. Glenmark Pharmaceuticals (Nigeria) Ltd 24. Glenmark Pharmaceuticals Malaysia Sdn Bhd 25. Glenmark Pharmaceuticals (Australia) Pty Ltd 26. Glenmark Pharmaceuticals (Oty) Ltd 27. Glenmark Pharmaceuticals (Oty) Ltd 27. Glenmark Pharmaceuticals (Oty) Ltd 28. Glenmark Pharmaceuticals (Oty) Ltd 29. Glenmark P B.V.(Formerly known as Glenmark Pharmaceuticals Canada Inc.) 32.Glenmark Pharmaceuticals Kenya Ltd 33.Glenmark Therapeutics AG 34. Viso Farmaceutica S.L., Spain 35. Glenmark Pharmaceuticals Distribution s.r.o. 37. Glenmark Pharmaceuticals Nordic AB 38. Glenmark Ukraine LLC 39. Glenmark Pharmaceuticals Ecuador S.A.

For and on behalf of the Board of Directors

Glenn Saldanha Chairman & Managing Director

Mumbai, February 8, 2018

FINANCIAL EXPRESS

FRIDAY, FEBRUARY 9, 2018

21

DCM LIMITED

Regd Office: Vikrant Tower, 4, Rajendra Place, New Delhi-110008 CIN- L74899DL1889PLC000004, Ph: (011)25719967, Fax: (011) 25765214 Email Id: investors@dcm.in, Website: www.dcm.in

EXTRACT OF STATEMENT OF UNAUDITED FINANCIAL RESULTS FOR THE 3RD QUARTER AND NINE MONTHS ENDED DECEMBER 31, 2017 (Rs in Lacs)

			Standalone		Consolidated						
Sr. No.	Particiliare	Quarter ended 31.12.2017	Corresponding quarter ended 31.12.2016		Quarter ended 31.12.2017	Corresponding quarter ended 31.12.2016	Nine months ended 31.12.2017				
		Unaudited	Unaudited	Unaudited	Unaudited	Unaudited	Unaudited				
1	Total income from operations	21,480	26,268	71,930	21,480	26,268	71,931				
2	Net Profit/(Loss) for the period (before tax, exceptional and extraordinary items)	(819)	(623)	(3,655)	(905)	(616)	(3,923)				
3	Net Profit/(Loss) for the period before tax (after exceptional and extraordinary items)*	(819)	152	(3,655)	(905)	159	(3,923)				
4	Net Profit/(Loss) for the period after tax (after exceptional and extraordinary items)*	(817)	106	(3,653)	(903)	112	(3,921)				
5	Total comprehensive income for the period	(867)	90	(3,777)	(953)	95	(4,045)				
6	Equity Share Capital	1,867	1,867	1,867	1,867	1,867	1,867				
7	Earnings per share (of Rs. 10 each) (Not annualized)										
	(i) Basic	(4.37)	0.57	(19.56)	(4.83)	0.60	(20.99)				
	(ii) Diluted	(4.37)	0.57	(19.56)	(4.83)	0.60	(20.99)				

*Includes exceptional items of Rs. 775 lacs for the quarter and nine months ended December 31, 2016 represents the recovery of amount from jointly controlled entity pursuant to the settlement reached by the Company. NOTES:

1 The above financial results have been reviewed by the Audit Committee and approved by the Board of Directors of the Company at their respective meeting(s) held on February 8, 2018. The Limited Review Report of the Statutory Auditors is being filed with the BSE Limited and National Stock Exchange of India Limited.

The above is an extract of the detailed unaudited financial results of the Company for the 3rd quarter and nine months ended December 31, 2017 filed with the Stock Exchanges (i.e. BSE Limited and National Stock Exchange of India Limited) under Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The detailed unaudited financial results of the Company for the 3rd quarter and nine months ended December 31, 2017 are available on the Stock Exchanges website(s) http://www.nseindia.com and http://www.bseindia.com and Company's website www.dcm.in.

Standalone (Ind AS)

For and on behalf of the Board For DCM Limited Dr. Vinay Bharat Ram

Place: New Delhi Date: February 08, 2018 Chairman and Managing Director



CIN: L22210MH1987PLCO44505

Regd. Office: Empire Mills Complex, 414, Senapati Bapat Marg, Lower Parel, Mumbai - 400 013 Telephone: 022-61646000, Website: www.tcpl.in, E-mail: info@tcpl.in

Extract of Unaudited Standalone Financial Results for the Quarter/Nine Months ended 31st December 2017

(₹ in lacs except per share data)

Quarter ended 31.12.2017	Nine Months ended 31.12.2017	Quarter ended 30.12.2016
Unaudited	Unaudited	Unaudited
21143.25	56886.50	17266.55
2723.72	5367.17	-
18419.53	51519.33	17266.55
975.32	2296.58	1476.35
718.02	1616.43	962.88
725.78	1567.73	948.64
910.00	910.00	870.00
8.06	18.15	11.07
	ended 31.12.2017 Unaudited 21143.25 2723.72 18419.53 975.32 718.02 725.78 910.00	ended 31.12.2017 Unaudited Unaudited 21143.25 56886.50 2723.72 5367.17 18419.53 51519.33 975.32 2296.58 718.02 1616.43 725.78 1567.73 910.00 910.00

Note:

- 1. The audit committee has reviewed the above results and the Board of Directors has approved the above results and its release at their respective meetings held on 7th February 2018. The Statutory Auditors of the Company have carried out a Limited Review of the aforesaid results.
- 2. The above is an extract of the detailed format of the standalone Financial Results for the quarter and nine months ended on 31st December 2017 filed with the Stock Exchanges under Regulation 33 of the SEBI (Listing and Other Disclosure Requirements) Regulations, 2015.
- The full format of the standalone Financial Results for the guarter and nine months ended on 31st December 2017 is available on the Stock Exchanges' websites (www.bseindia.com/www.nseindia.com) and the Company's Website www.tcpl.in.

For TCPL Packaging Limited

Consolidated (IFRS)

Place: Mumbai Date: 07.02.2018

Saket Kanoria Managing Director DIN:-00040801

glenmark

PHARMACEUTICALS LTD.

Registered Office: B/2, Mahalaxmi Chambers, 22, Bhulabhai Desai Road, Mumbai 400 026.

Corporate Office: Glenmark House, B. D. Sawant Marg, Chakala, Andheri (East), Mumbai 400 099.

Tel: 91 22 4018 9999 Fax: 91 22 4018 9986 Email: complianceofficer@glenmarkpharma.com Website: www.glenmarkpharma.com CIN: L24299MH1977PLC019982

Statement of Profit and Loss for the quarter and nine months ended 31 December, 2017

Consolidated (Ind AS)

(₹ in Millions)

	Deutlessless												2						
	(Refer notes below)			Quarter ended 31-12-2016 (Unaudited)	ended 31-12-2017	Nine Months ended 31-12-2016 (Unaudited)	Year ended 31-03-2017 (Audited)		Quarter ended 30-09-2017 (Unaudited)		ended 31-12-2017				Quarter ended 30-09-2017 (Unaudited)		ended 31-12-2017	Nine Months ended 31-12-2016 (Unaudited)	Year ended 31-03-2017 (Audited)
	Revenue from operations	2		· ·		P P	**************************************		7	-					8	70			
	(a) Net sales	14,592.46	16.195.53	21,149.46	45.897.25	57,562.69	76,948.30	21,715.05	22,234.40	24.629.53	67,243.39	65.456.72	89,700.86	21.715.05	22.234.40	24,629.53	67,243.39	65.456.72	89,700.86
	(b) Other operating income	973.03		87				321.57	0.00	720.55	30	1,828.26		321.57	331.50	720.55	989.15	1,828.26	
	Revenue from operations	15,565.49	0.000017667777	21,917.79			7,000,000,000	22,036.62		T 3.05 3 3 3 3 3 3 3 3 5 5 5 5 5 5 5 5 5 5 5			91,856.81	22,036.62				67,284.98	
Li	Other income	372.32						(231.64)		145.67		886.52	373.65	(231.64)	297.26			885.77	372.90
L	Total income (I + II)		929.79		580			30 00 000						10		7.71			
IN.	Expenses	10,001.01	,	,00	10,002.00	02,200.01	02,101.00	21,001.00	22,000.10	20,1000	00,101102		02,200110	21,00 1100		20,100101	00,101102	00,110.10	02,220
	Cost of materials consumed	5,224.70	4,848.22	5.615.27	15,073.13	16,941.38	22,420.13	5,051.16	5,443.85	5.600.88	15,351.68	18,358.44	23,548.13	5,051.16	5,443.85	5,600.88	15,351.68	18,358.44	23,548.13
	Purchase of stock-in-trade	891.95	664.07	35,500,500				1,862.11	1,342.18	1,578.60				1,862.11	1,342.18				
	Changes in inventories of finished goods,			53445757555				***************************************	20.4		V. 1. 2. 2. 2. 2. 2. 2. 2. 2. 2. 2. 2. 2. 2.	0054 5050 5050		70.100 min.o.	114.01.020.003		113.4.1.3.3.4.6.5.		
	work-in-progress and stock-in-trade	(304.49)	584.97	72.99	171.14	(836.19)	(835.17)	902.44	726.44	(1,189.09)	1,377.51	(3,569.40)	(4,596.07)	902.44	726.44	(1,189.09)	1,377.51	(3,569.40)	(4,596.07)
	Employee benefits expense	2,553.98	3,264.26	2,274.07	7,895.91	6,933.45	9,144.71	4,659.42	5,572.30	4,016.81	14,075.68	12,560.66	16,408.06	4,659.42	5,572.30	4,016.81	14,075.68	12,560.66	16,408.06
	Finance costs	469.99	474.41	495.39	1,401.76	1,028.81	1,526.02	704.74	698.44	617.37	2,111.79	1,676.48	2,373.18	704.74	698.44	617.37	2,111.79	1,676.48	2,373.18
	Depreciation and Amortisation expense	295.53	288.93	263.36	883.86	776.15	1,049.32	753.84	752.28	625.26	2,283.44	1,954.64	2,643.68	895.18	874.05	788.44	2,646.43	2,322.33	3,167.61
	Other expenses	4,531.39	3,262.04	4,849.88	12,080.19	12,890.43	18,568.95	6,334.56	5,597.17	7,692.64	18,728.84	20,421.97	28,938.49	6,334.61	5,597.55	7,692.38	18,729.98	20,421.97	28,938.49
	Total expenses (IV)	13,663.05	13,386.90	14,232.48	39,755.07	39,843.66	54,543.92	20,268.27	20,132.66	18,942.47	59,742.39	54,987.53	76,506.67	20,409.66	20,254.81	19,105.39	60,106.52	55,355.22	77,030.60
١ ١	Profit/(loss) before exceptional items and tax (III - IV)	2,274.76	3,774.26	8,748.89	9,247.56	22,445.35	27,893.47	1,536.71	2,730.50	6,553.28	8,708.63	13,183.97	15,723.79	1,395.32	2,608.35	6,389.62	8,344.50	12,815.53	15,199.11
V	Exceptional items (refer note 5)	-	-	-	-	-	2,364.51	-	-	-	-	-	809.49	-	-	-	-	-	2,597.59
VI	Profit/(loss) before tax (V - VI)	2,274.76	3,774.26	8,748.89	9,247.56	22,445.35	25,528.96	1,536.71	2,730.50	6,553.28	8,708.63	13,183.97	14,914.30	1,395.32	2,608.35	6,389.62	8,344.50	12,815.53	12,601.52
VII	Tax expense :	888	.23	- 38	30	93	6.9	100	200	801	100	***	88	90	- 03	19	88		
	Current tax	489.59	801.35	1,946.54	1,973.25	4,888.25	6,040.24	529.15	976.19	1,498.51	2,295.47	4,535.33	6,190.43	529.15	976.19	1,498.51	2,295.47	4,535.33	6,177.97
	Deferred tax	(155.99)	(305.88)	(310.72)	(654.04)	(302.31)	(1,917.36)	(39.87)	(386.89)	283.76	(109.27)	(626.03)	(2,363.66)	(68.41)	(410.95)	293.14	(183.43)	(692.36)	(2,735.66)
D	Profit/(loss) for the period (VII - VIII)	1,941.16	3,278.79	7,113.07	7,928.35	17,859.40	21,406.08	1,047.43	2,141.20	4,771.01	6,522.43	9,274.67	11,087.53	934.58	2,043.11	4,597.97	6,232.46	8,972.56	9,159.21
)	Other comprehensive income																		
	A (i) Items that will not be reclassified to profit or loss	(11.92)	(26.09)	(41.17)	(46.61)	(94.20)	(34.40)	(2.84)	50.33	(35.32)	32.03	(77.00)	(47.01)	(2.84)	50.33	(35.32)	32.03	(77.00)	(47.01)
	(ii) Income tax relating to items that will not be reclassified to profit or loss	4.12	9.02	5.87	16.13	23.90	11.70	2.94	(1.02)	12.00	5.90	24.75	13.29	2.94	(1.02)	12.00	5.90	24.75	13.29
	B (i) Items that will be reclassified to profit or loss	-			-	١.		101.42	(14.41)	(392.75)	(267.50)	473.36	(1,750.00)	62.21	55.73	(333.95)	(232.25)	520.83	(1,758.73)
	(ii) Income tax relating to items that will be reclassified to profit or loss	-		112	- 1	_	-			-		82		1 12		2	-	882	-
X	Total comprehensive income	1,933.36	3,261.72	7,077.77	7,897.87	17,789.10	21,383.38	1,148.95	2,176.10	4,354.94	6,292.86	9,695.78	9,303.81	996.89	2,148.15	4,240.70	6,038.14	9,441.14	7,366.76
XI	Total comprehensive income attributable to:																		
	- Non-controlling interests	3	2	-	-	-	9	0.64	(0.32)	0.71	0.45	0.71	(0.46)	0.64	(0.32)	0.71	0.45	0.71	(0.46)
	- Owners of the Company	1,933.36	3,261.72	7,077.77	7,897.87	17,789.10	21,383.38	1,148.31	2,176.42	4,354.23	6,292.41	9,695.07	9,304.27	996.25	2,148.47	4,239.99	6,037.69	9,440.43	7,367.22
XII	Earning Per Share (of Re 1/- each) (not annualised)																		
57.755.05	Basic Earnings Per Share (in Rupees)	6.88	11.62	25.21	28.10	63.29	75.86	3.71	7.59	16.91	23.12	32.87	39.29	3.31	7.24	16.29	22.09	31.80	32.46
	Diluted Earnings Per Share (in Rupees)	6.88	11.62	25.20	28.09	63.28	75.84	3.71	7.59	16.90	23.11	32.86		3000.00	7.24	16.29	22.08		
No																-			

Notes:

- The above results were reviewed by the Audit Committee of the Board at its meeting held on 7 February, 2018 and approved at the meeting of the Board of Directors held on 8 February, 2018.
- 2 The results for the quarter and nine months ended 31 December, 2017 presented were subjected to a "Limited Review" by the Statutory auditors of the Company. An unqualified report was issued by them therein.
- 3 The Company operates in one reportable business segment i.e., Pharmaceuticals.
- 4 As at 31 December, 2017, pursuant to Employee Stock Option Scheme 2003, no options were outstanding, which upon exercise are convertible into equivalent number of equity shares. 5 Exceptional items:
- year ended 31 March, 2017 and considering the uncertainty around repatriation, the Company believes it's appropriate to impair such investments and trade receivables from the said subsidiary. Consolidated: Exceptional items for year ended 31 March, 2017 represents impairment loss relating to certain intangibles assets under development owing to the Company's future research and development strategy for such products.
- 6 The Company has voluntarily presented the consolidated results in accordance with the recognition and measurement principles as per the IFRS in the format as per the regulation 33(1)(c) of the SEBI (Listing and Disclosure Requirements) Regulations, 2015.
- Post implementation of Goods and Service Tax (GST) with effect from 1 July, 2017, revenue from operations for the earlier period includes excise duty which is now subsumed in the GST. Revenue from operations for the nine months ended 31 December, 2017 includes excise duty upto 30 June, 2017. Accordingly, revenue from operations for the guarter and nine months ended 31 December, 2017 are not comparable with those of previous periods presented.

Stand-alone: Exceptional items for year ended 31 March, 2017 represents impairment loss relating to investment and trade receivables from the Company's subsidiary in Venezuela. The Company has not received approvals from the Venezuelan government to repatriate any amounts during the

8 The list of subsidiaries as of 31 December, 2017 is provided in Annexure A.

Annexure A

List of entities included in the consolidated financial results for the quarter and Nine Months ended 31 December 2017.

Name of Entities:

1.Glenmark Pharmaceuticals (Europe) R&D Ltd., U.K. 2.Glenmark Pharmaceuticals Europe Ltd., U.K. 3.Glenmark Pharmaceuticals S.R.O. 5.Glenmark Pharmaceuticals S. A. 6.Glenmark Holding S.A. 7.Glenmark Pharmaceuticals S.R.L 8.Glenmark Pharmaceuticals SP z.o.o. 9.Glenmark Pharmaceuticals Inc. (formerly known as Glenmark Generics Inc.) 10.Glenmark Therapeutics Inc. 11.Glenmark Farmaceutica Ltda 12.Glenmark Generics S.A 13.Glenmark Pharmaceuticals Mexico, S.A. DE C.V. 14. Glenmark Pharmaceuticals Peru SAC 15. Glenmark Pharmaceuticals Colombia SAS, Colombia (Formerly known as Glenmark Pharmaceuticals Colombia Ltda., Colombia) 16. Glenmark Uruguay S.A. 17. Glenmark Pharmaceuticals Venezuela, C.A 18. Glenmark Dominicana SRL 19. Glenmark Pharmaceuticals Egypt S.A.E. 20. Glenmark Pharmaceuticals FZE 21. Glenmark Philippines Inc. 23. Glenmark Pharmaceuticals (Nigeria) Ltd 24. Glenmark Pharmaceuticals Malaysia Sdn Bhd 25. Glenmark Pharmaceuticals (Australia) Pty Ltd 26. Glenmark Pharmaceuticals South Africa (pty) Ltd 28. Glenmark Pharmaceuticals (Thailand) Co. Ltd 29. Glenmark Pharmaceuticals B.V.(Formerly known as Glenmark Generics B.V.) 30. Glenmark Arzneimittel Gmbh 31. Glenmark Pharmaceuticals Canada Inc. (formerly known as Glenmark Generics Canada Inc.) 32. Glenmark Pharmaceuticals Kenya Ltd 33. Glenmark Therapeutics AG 34. Viso Farmaceutica S.L., Spain 35. Glenmark Specialty SA 36. Glenmark Pharmaceuticals Distribution s.r.o. 37. Glenmark Pharmaceuticals Nordic AB 38. Glenmark Ukraine LLC 39. Glenmark-Pharmaceuticals Ecuador S.A.

For and on behalf of the Board of Directors

Glenn Saldanha Chairman & Managing Director

Mumbai, February 8, 2018